The role of melatonin in Multiple Sclerosis.
Study Goal
The researchers aimed to summarize the role of melatonin in immune processes relevant to experimental autoimmune encephalomyelitis (EAE), multiple sclerosis (MS), and current clinical trials of melatonin supplementation in MS patients.
Results Summary
The abstract highlights melatonin's pleiotropic effects, including immunomodulating properties, and suggests its dysregulation is linked to autoimmune diseases like MS. It proposes melatonin as a potential therapeutic target for MS, based on evidence of dysregulated secretion in patients.
Population
MS patients and experimental models (EAE).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin | neutral | wake-sleep rhythm | - | - | regulates | #1 |
melatonin | neutral | antinociceptive, antidepressant, anxiolytic, and immunomodulating properties | - | - | exerts | #2 |
dysregulation of melatonin secretion | neutral | pathogenesis of various autoimmune diseases | - | - | associated with | #3 |
melatonin secretion | neutral | - | MS patients | - | dysregulated | #4 |
melatonin | neutral | - | MS patients | - | could be a potential target for therapeutic intervention | #5 |
Melatonin is a neurohormone mainly produced by the pineal gland following a circadian rhythm. It is characterized as a pleiotropic factor because it not only regulates the wake-sleep rhythm but also exerts antinociceptive, antidepressant, anxiolytic, and immunomodulating properties. Recent studies suggest that dysregulation of melatonin secretion is associated with the pathogenesis of various autoimmune diseases, such as, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS). MS is an autoimmune disorder characterized by an abnormal immune response directed against the myelin sheath in the central nervous system, demyelination, oligodendrocyte death, and axonal degeneration. Recent evidence reveals that melatonin secretion is dysregulated in MS patients, suggesting that melatonin could be a potential target for therapeutic intervention. Here, we summarize the available literature regarding the role of melatonin in immune processes relevant for experimental autoimmune encephalomyelitis (EAE), MS, and the current clinical trials of melatonin supplementation in MS patients.